Immunohistochemistry as a diagnostic aid in cervical pathology

Effect of storage on p63 immunohistochemistry: a time-course study

One of the problems with immunohistochemistry is that storage of unstained slides can have a detectable negative effect on the intensity of staining for various antigens. This has not been well studied for the p63 antigen. A time-course study was performed to evaluate the effect of storage on the intensity of p63 immunohistochemical staining. Slides from various breast lesions/foci were stained with a p63 antibody on day 0 and after storage at room temperature for 2, 4, and 8 weeks. A p63 intensity score, ranging from 0 to 300, was calculated using the intensity (0, 1, 2, or 3+) and percentage of peripheral myoepithelial cell staining (0% to 100%). There was a progressive decline in the p63 intensity score with time with the differences between day 0 and 2 weeks and 2 and 4 weeks being statistically significant (P=0.037 and 0.001, respectively), whereas that between 4 and 8 weeks was not (P=0.075). These findings confirm a time-dependent decline in p63 immunostaining intensity evident as early as with 2 weeks of storage and still present after 8 weeks. This should be considered in the evaluation of p63 immunostains performed on stored unstained sections, both in diagnostic surgical pathology and in translational research studies.

Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies

p16(INK4a), an indirect marker of cell cycle dysregulation, is commonly expressed in cervical dysplasias and carcinomas associated with high risk human papillomavirus (HR-HPV) infections. Although p16(INK4a) immunohistology is routinely used as a cost effective surrogate marker, many of the published articles are confusing and contradictory. The discrepancies can be ascribed to a multitude of factors operating at the molecular, technical and interpretative levels. In the first place, our simplistic model of viral mediated oncogenesis is speculative and fails to account for all the known biomolecular changes. Unresolved technical issues include the variables of tissue fixation, antibody dilution, antibody isotype and clone, and the sensitivity of the particular detection method. Within any controlled staining method, strong diffuse or 'block' immunoreactivity in squamous cells may be found in moderate/severe dysplasia (CIN 2/3) and invasive squamous carcinoma. In contrast, focal or multifocal reactivity in squamous cells may be artefactual, related to low risk or HR-HPV. p16(INK4a) is less reliable when dealing with glandular lesions since considerable overlap exists between reactive and dysplastic lesions. In addition not all glandular dysplasias/carcinomas are HR-HPV related, nor are all p16(INK4a) immunoreactive lesions associated with HR-HPV. We conclude that p16(INK4a) immunoperoxidase shows greater specificity than sensitivity for squamous lesions; in comparison, glandular dysplasias/carcinomas show reduced specificity and sensitivity. Like all cell cycle regulatory proteins, the future diagnostic role of p16(INK4a) is limited. The ideal diagnostic molecular test for cervical dysplasias will detect a HR-HPV related product after, but not before, cell transformation and will reliably predict those cases yet to experience disease progression.

Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study

BACKGROUND

To determine the clinical and pathologic prognostic factors in surgically treated patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix (SCNEC).

PATIENTS AND METHODS

We retrospectively reviewed a total of 68 patients with FIGO stage IB-IIA SCNEC surgically treated from January 1997 to December 2003 in Korea.

RESULTS

Of the 68 patients, 43 had FIGO stage IB1 SCNEC, 15 had stage IB2, and 10 had stage IIA. Seven were treated with radical surgery alone; 11 with neoadjuvant chemotherapy (NACT) followed by radical surgery; 24 with radical surgery followed by adjuvant chemotherapy; and 26 with radical surgery followed by adjuvant radiation or chemoradiation. After a median follow-up of 44 months (range, 6-113 months), the 2-year and 5-year survival rates for all patients were 64.6% and 46.6%, respectively. Univariate and multivariate analysis showed that FIGO stage was predictive of poor prognosis. Patients who received NACT showed poorer prognosis than those who did not receive NACT. Adjuvant chemoradiation did not improve survival compared with adjuvant chemotherapy alone.

CONCLUSIONS

FIGO stage may act as a surrogate for factors prognostic of survival. Primary radical surgery followed by adjuvant chemotherapy is the preferred treatment modality for patients with early stage SCNEC.